SLNO vs. LRMR, RYTM, EDAP, FONR, RMTI, TMDX, ITGR, LIVN, CNMD, and INMD
Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include Larimar Therapeutics (LRMR), Rhythm Pharmaceuticals (RYTM), Edap Tms (EDAP), FONAR (FONR), Rockwell Medical (RMTI), TransMedics Group (TMDX), Integer (ITGR), LivaNova (LIVN), CONMED (CNMD), and InMode (INMD). These companies are all part of the "medical" sector.
Larimar Therapeutics (NASDAQ:LRMR) and Soleno Therapeutics (NASDAQ:SLNO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
Larimar Therapeutics presently has a consensus price target of $21.33, indicating a potential upside of 117.24%. Soleno Therapeutics has a consensus price target of $60.33, indicating a potential upside of 28.34%. Given Soleno Therapeutics' higher possible upside, equities research analysts clearly believe Larimar Therapeutics is more favorable than Soleno Therapeutics.
91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 4.3% of Larimar Therapeutics shares are owned by insiders. Comparatively, 12.3% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Soleno Therapeutics had 5 more articles in the media than Larimar Therapeutics. MarketBeat recorded 7 mentions for Soleno Therapeutics and 2 mentions for Larimar Therapeutics. Larimar Therapeutics' average media sentiment score of 0.87 beat Soleno Therapeutics' score of 0.59 indicating that Soleno Therapeutics is being referred to more favorably in the news media.
Larimar Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Soleno Therapeutics has a beta of -1.4, indicating that its stock price is 240% less volatile than the S&P 500.
Soleno Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.
Soleno Therapeutics received 269 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. Likewise, 71.43% of users gave Soleno Therapeutics an outperform vote while only 63.27% of users gave Larimar Therapeutics an outperform vote.
Soleno Therapeutics' return on equity of -35.69% beat Larimar Therapeutics' return on equity.
Summary
Soleno Therapeutics beats Larimar Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Soleno Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soleno Therapeutics Competitors List
Related Companies and Tools
